ArticleBrain and behavior2025
Demographic and Comorbidity Barriers to Therapy Revision in Epilepsy: A Population-Wide Investigation.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Demographic and Comorbidity Barriers to Therapy Revision in Epilepsy: A Population-Wide Investigation.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe first antiseizure medication (ASM) fails due to side effects or continued seizures in about half of cases. We used population-wide register data to assess whether patient demographics or comorbidities influenced likelihood of therapy revision in order to identify gaps in access to adequate epilepsy follow-up.
methodsNational registers identified all adults in Sweden with incident epilepsy between 2007 and 2019 and initial ASM monotherapy based on prescription data. Therapy revision was defined as changing medication or starting a second ASM. Cox proportional hazard models were used to evaluate clinical factors associated with therapy revision. Sensitivity analyses were restricted to patients surviving for 2 or 4 years, or to specific first monotherapies.
resultsThe final cohort included 44,185 individuals. Age (HR = 0.993, 95% CI: 0.992-0.993), cerebrovascular disease (HR = 0.81, 95% CI: 0.78-0.85), and dementia (HR = 0.63, 95% CI: 0.58-0.69) were associated with reduced likelihood of revising the first ASM. Women (HR = 1.14, 95% CI: 1.10-1.19), patients with brain infections (HR = 1.21, 95% CI: 1.08-1.35), and patients with brain tumors (HR = 1.31, 95% CI: 1.23-1.39) were more likely to revise their first treatment. DISCUSSION: Older persons with epilepsy and those with cerebrovascular disease or dementia are less likely to change the first ASM, suggesting a disadvantage for older persons with epilepsy and those with brain morbidities associated with aging in current health care systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.